MDT Nov 2024 60.000 put
| Previous close | 0.2800 |
| Open | 0.4600 |
| Bid | 0.0700 |
| Ask | 2.2000 |
| Strike | 60.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.2800 - 0.4600 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
ZacksMedtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
BenzingaMedtronic's Q4 Earnings: Medical Device Giant Clocks Strong Sales From Neurology Devices, Hikes Dividend
Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion. Revenue increased 0.5%, as reported, and 5.4% organic. The company’s organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments. The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45. Related: Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replace
ZacksMedtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
